Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2006 5
2007 1
2011 3
2012 1
2013 1
2014 5
2015 7
2016 3
2017 1
2019 1
2020 1
2021 1
2022 1
2023 2
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Thatcher N, et al. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Free article. Clinical Trial.
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR. Christopoulos P, et al. Among authors: geldart t. JCO Precis Oncol. 2024 Mar;8:e2300555. doi: 10.1200/PO.23.00555. JCO Precis Oncol. 2024. PMID: 38513170 Free PMC article.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study.
Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Holer L, Hayoz S, Früh M, Ahmed S, Bhagani S, Steele N, Gray HL, Robinson SD, Davidson M, Cox S, Khalid T, Geldart TR, Nolan L, Scott DC, Hennah L, Newsom-Davis T, Rathbone E, Handforth C, Denton A, Merchant S, Blackhall F, Mauti LA, Califano R, Rothschild SI. Moliner L, et al. Among authors: geldart tr. JTO Clin Res Rep. 2024 Oct 17;6(1):100744. doi: 10.1016/j.jtocrr.2024.100744. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39802819 Free PMC article.
Anti-CD 40 monoclonal antibody.
Geldart T, Illidge T. Geldart T, et al. Leuk Lymphoma. 2005 Aug;46(8):1105-13. doi: 10.1080/10428190500085255. Leuk Lymphoma. 2005. PMID: 16085550 Review.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Popat S, Januszewski A, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Morris C, Ngai Y, Hughes L, Hackshaw A, Wilson W. Popat S, et al. Among authors: geldart t. Br J Cancer. 2025 Feb;132(3):245-252. doi: 10.1038/s41416-024-02901-6. Epub 2024 Dec 5. Br J Cancer. 2025. PMID: 39639088 Free PMC article. Clinical Trial.
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW; STAMPEDE investigators. Gillessen S, et al. Lancet Oncol. 2025 Aug;26(8):1018-1030. doi: 10.1016/S1470-2045(25)00231-1. Epub 2025 Jul 7. Lancet Oncol. 2025. PMID: 40639383 Free PMC article. Clinical Trial.
37 results